Alexandra Dmitrievna Chernichkina

Alexandra Dmitrievna Chernichkina

Auto-generated profile, based on publicly available information

Alexandra Dmitrievna Chernichkina

Hospital Therapy No. 1, Sechenov First Moscow State Medical University, Moscow 119991, Russia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2025 in Kardiologiia
Verified
Journal Article
Closed access
YKYu. Yu. Kirichenko
Yu. Yu. Kirichenko
VVV. G. Varsieva
V. G. Varsieva
KSKsenia Shestakova
Ksenia Shestakova
ACA. D. Chernichkina
A. D. Chernichkina
APA. V. Palienko
A. V. Palienko
SASvetlana Appolonova
Svetlana Appolonova
Aim To determine the array of metabolomic profiles and structural and functional parameters of the vascular wall associated with the risk of cardiovascular toxicity of antitumor therapy (ATT) in oncohematological patients. Material and methods This study included 59 patients, among them 34 patients with lymphomas (non-Hodgkin and Hodgkin lymphoma) and 25 with multiple myeloma. Before and after 3 courses of ATT (anthracyclines, proteasome inhibitors), finger photoplethysmography and transthoracic echocardiography were performed as well as metabolomic profiling (98 metabolites) by high-performance liquid chromatography in combination with tandem mass spectrometry. Statistical analysis of the results included parametric and nonparametric tests, logistic regression, and cross-validation. Results The study showed that even before the initiation of ATT, cancer patients had signs of endothelial dysfunction and increased vascular wall stiffness (increased aSI, RI, and IO indices), which significantly worsened after the specific treatment. Metabolomic profiling identified a set of metabolites associated with the risk of cardiovascular toxicity, including increased concentrations of amino acids (asparagine, serine, glutamate, glutamine, taurine, citrulline), short-chain acylcarnitines (C18:1 OH-carnitine, C16:1 OH-carnitine, C14OH-carnitine, C2 carnitine), choline metabolism intermediates (TMAO, dimethylglycine, choline), tryptophan metabolites (hydroxyindoleacetic acid, kynurenic acid). Additionally, a logistic regression model was developed based on the analysis of the metabolomic profile, which showed a high prognostic power (AUC = 0.84) for predicting cardiovascular toxicity of ATT. Conclusion The study identified key metabolites and structural and functional parameters of blood vessels that allow detection of an increased risk of cardiovascular complications of ATT in patients with lymphomas and multiple myeloma before the initiation of a specific treatment. Increased concentrations of amino acids, acylcarnitines, and choline metabolites may serve as an additional risk factor for the onset/progression of cardiovascular complications. The proposed integrative approach, including both metabolomic profiling and non-invasive assessment of the vascular wall condition, opens broad prospects for personalized cardioprotection of cancer patients and more accurate monitoring of the cardiovascular status during ATT.

31 October 2024 in Kardiologiia
Verified
Journal Article
Open access
PDF file
YKYu. Yu. Kirichenko
Yu. Yu. Kirichenko
III. S. Ilgisonis
I. S. Ilgisonis
ACA. D. Chernichkina
A. D. Chernichkina
APA. V. Palienko
A. V. Palienko
OBO. I. Buduscheva
O. I. Buduscheva
YBYuri Belenkov
Yuri Belenkov
Aim . To present the four-year experience and the accomplishments of the Scientific and Practical Cardio-Oncology Center of the Sechenov University. Material and methods . The records of patients referred for cardio-oncology consultation from January 2020 through March 2024 were retrospectively analyzed. The patients’ cardiovascular (CV) status was assessed at baseline and after optimizing the cardiac therapy during the antitumor treatment. The endpoints were the completion of all antitumor therapy courses and the level of overall and CV mortality. Results . Among 233 enrolled patients (66% women), a considerable part belonged to the group of high/very high cardio-oncological risk (n=134, 57%). Various cardiovascular toxicities were observed in 22% of patients. At baseline, these patients significantly more frequently had heart failure and ischemic heart disease as well as previous radiation and chemotherapy. After the optimization of cardiac therapy, 88% of patients successfully completed all scheduled treatments. The overall mortality, including the CV mortality, was 14% (n=7). Conclusion . Creation of cardio-oncological services allows considerably reducing the probability of adverse CV events during the antitumor therapy and successfully completing all scheduled treatments in most patients. .

Verified
Journal Article
Open access
PDF file
DKDaria Kutsakina
Daria Kutsakina
ACAlexandra Dmitrievna Chernichkina
Alexandra Dmitrievna Chernichkina
NNNadezhda Nikolaeva
Nadezhda Nikolaeva
OVOlga O. Voronkova
Olga O. Voronkova
OTOlga Valerevna Tashchyan
Olga Valerevna Tashchyan
APAlexander Sergeevich Panferov
Alexander Sergeevich Panferov
Background: Crohn‘s disease (CD) is frequently complicated by extraintestinal manifestations, including axial spondyloarthritis (axSpA). Both diseases share genetic (HLA-B27, IL23R, ERAP1/2) and immunopathological mechanisms (Th17/IL-23 axis). Their co-occurrence increases the risk of systemic complications such as AA amyloidosis. Case presentation: We report a 42-year-old male with HLA-B27-positive axSpA who developed CD shortly after initiating secukinumab (IL-17A inhibitor). Following discontinuation of secukinumab and surgical management of CD, the patient experienced rapidly progressive AA amyloidosis affecting the kidneys and intestines, leading to acute kidney injury and requiring hemodialysis. Potential triggering factors included a preceding intestinal infection and self-administered infrared physiotherapy. Conclusions: Coexistent CD and axSpA significantly increases the risk of severe AA amyloidosis. IL-17 inhibitors should be used with extreme caution in patients with subclinical or active CD. Early screenings for proteinuria and low-threshold biopsy are essential to detect AA amyloidosis. In patients with both conditions, TNF-α or IL-12/23 inhibitors are preferred over IL-17 blockade.